Company news

MannKind Corporation news in 2026

MannKind Corporation's news releases, calls and decks from 2026, newest first.

View company

MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026

October 29, 2026

MannKind to Participate in the Chardan Healthcare Conference

October 14, 2026

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

October 8, 2026

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

September 9, 2026

MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update

August 5, 2026

MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF

July 29, 2026

MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026

July 28, 2026

MannKind Announces FDA Approval of Furoscix ReadyFlow, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

July 27, 2026

MannKind Announces $50 Million Private Placement

July 24, 2026

MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease

July 24, 2026

MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D

June 22, 2026

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems

June 5, 2026

MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF

June 3, 2026

MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval

May 29, 2026

MannKind Announces FDA Approval of Afrezza®, the First and Only Inhaled Mealtime Insulin for Use in Children and Adolescents Aged 6 and Older Living with Diabetes

May 29, 2026

MannKind to Present at Jefferies Global Healthcare Conference

May 27, 2026

MannKind to Showcase New Data at ADA 2026 Advancing Understanding of Inhaled Insulin (Afrezza®) in Pediatric Care, Pregnancy and Use with Automated Insulin Delivery (AID) Systems

May 27, 2026

MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases

May 6, 2026

MannKind to Report First Quarter 2026 Financial Results on May 6, 2026

April 29, 2026

MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026

March 8, 2026

MannKind Announces Settlement of Convertible Senior Notes

March 4, 2026

MannKind to Participate in Upcoming Investor Conferences

March 3, 2026

MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 25, 2026

MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 19, 2026

MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

February 17, 2026

MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)

February 9, 2026

MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy

January 26, 2026

MannKind Provides Business Updates and 2026 Growth Drivers

January 8, 2026

Calls in 2026

Decks in 2026